Assessing gastric bypass in patients with type 2 diabetes
Gastric bypass when combined with lifestyle and medical management improves diabetes control in obese patients with type 2 diabetes mellitus, researchers report. The Diabetes Surgery Study, a long-range randomized clinical trial, compares the relative effectiveness of Roux-en-Y gastric bypass surgery combined with intensive medical management to that of intensive medical management alone. The 2- and 3-year follow-up results revealed that the addition of gastric bypass to lifestyle and medical management improved diabetes control in patients with type 2 diabetes mellitus. These results lay the groundwork for larger, long-term studies, which are now in year 5. The research informs risk and benefit assessments of the surgical approach to obesity.
Cross-disciplinary research sheds light on role of gut microbiota in obesity
Studies into gut microbiota are bringing new insight into obesity and weight management strategies. Gut microbiota may play a role in lessening the efficacy of sleeve gastrectomy, report University of Minnesota investigators who have been documenting changes in microbiota in these patients. Alexander Khoruts, MD, is collaborating with researchers in the Department of Surgery to have a better understanding of the microbiome in the obese patient. Cyrus Jahansouz will present findings at the clinical congress of the American College of Surgeons this October. Other university research also suggests that sleeve gastrectomy and Rouxen-Y gastric bypass may offer unique improvements in factors that drive type 2 diabetes. The investigators working with David Bernlohr, PhD, and researchers in the Department of Biochemistry seek to better understand these pathways.
Trial of medication for
teen obesity opens
University of Minnesota investigators are recruiting patients for a study of a glucagon-like peptide-1 receptor agonist (Bydureon) used as a therapy to enhance weight-loss maintenance in adolescents with severe obesity. The study will examine whether the pharmacological agent can prevent weight regain by targeting specific counter-regulatory mechanisms that emerge after weightloss. Participants who have lost 5% or more BMI through short-term meal replacement therapy will be randomly assigned to either a treatment or placebo group. Principal investigator is Aaron S. Kelly, PhD. For information, contact email@example.com.
Medications and new FDA-approved interventions aid patients in managing conditions associated with excess weight. Research into the gut microbiome may uncover yet other approaches to obesity.Continue reading
Unable to maintain weight loss, a patient opts for comprehensive weight management and bariatric surgery. At 12-months postprocedure, her glucose levels and blood pressure return to the normal range.Continue reading